Genuro at Moody Capital Disruptive Growth & Life Science Conference: ALS bet

On September 9, 2026, biotech company Genuro made its debut at the Moody Capital Disruptive Growth & Life Science Conference to discuss its high-stakes approach to treating amyotrophic lateral sclerosis (ALS) through the study of human endogenous retroviruses (HERVs). Genuro's lead ALS program is targeting a potential human-grade drug supply by July 2027, but acknowledges significant scientific and execution uncertainties.

The company believes HERVs, which make up around 8% of the human genome, may play a role in the development of ALS, multiple sclerosis, and schizophrenia.

Genuro is developing a monoclonal antibody-based approach to neutralize HERV-K and HERV-W envelope proteins, which can become harmful when dysregulated in adulthood. The company is working with manufacturing partner Polymun and has secured $80 million in funding through the 2027 U.S. defense appropriations bill and Congressionally Directed Medical Research Programs. Genuro's initial focus is on ALS, with potential extensions to other HERV-related conditions like multiple sclerosis and schizophrenia.

The company has €180 million in prior European R&D, 25 approved patents, and a clean cap table after acquiring assets from a Swiss bankruptcy. Genuro's manufacturing plan, led by Mike Taylor and Rick Panicucci, aims to produce a human-grade drug product by July 2027. The timeline and funding sources make Genuro one of the most advanced ALS programs in the pipeline, with a potential FDA approval by 2029.